Thousand Oaks biotech giant Amgen announced Oct. 24 that it had slashed the price of its cholesterol medication Repatha from $14,000 to $5,850, a reduction of nearly 60 percent. The move follows similar reductions and rebate programs by Sanofi and Regeneron for its product Praluent, which was selected as the preferred PCSK9 inhibitor therapy by…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
